TY - JOUR
T1 - Gene mutation and surgical technique
T2 - Suggestion or more?
AU - Kawaguchi, Yoshikuni
AU - Lillemoe, Heather A.
AU - Vauthey, Jean Nicolas
N1 - Funding Information:
This article was supported in part by the National Institutes of Health, United States ( T32 CA 009599 ) and the MD Anderson Cancer Center Support Grant, United States CA016672 .
Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2020/6
Y1 - 2020/6
N2 - Advancements in chemotherapy and molecular targeted therapy have improved long-term outcomes for patients with resectable colorectal liver metastases (CLM). RAS mutation status was an original focus as a molecular biomarker as it predicted treatments response to anti-epidermal growth factor receptor agents. More recently, studies have incorporated somatic mutation data in analyses pertaining to surgical outcomes and prognosis. This evidenced-based review covers the implications of somatic mutations in patients undergoing resection of CLM.
AB - Advancements in chemotherapy and molecular targeted therapy have improved long-term outcomes for patients with resectable colorectal liver metastases (CLM). RAS mutation status was an original focus as a molecular biomarker as it predicted treatments response to anti-epidermal growth factor receptor agents. More recently, studies have incorporated somatic mutation data in analyses pertaining to surgical outcomes and prognosis. This evidenced-based review covers the implications of somatic mutations in patients undergoing resection of CLM.
KW - Colorectal liver metastasis
KW - Multiple gene mutation
KW - Somatic gene mutation
UR - http://www.scopus.com/inward/record.url?scp=85069696412&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069696412&partnerID=8YFLogxK
U2 - 10.1016/j.suronc.2019.07.004
DO - 10.1016/j.suronc.2019.07.004
M3 - Review article
C2 - 31351766
AN - SCOPUS:85069696412
SN - 0960-7404
VL - 33
SP - 210
EP - 215
JO - Surgical Oncology
JF - Surgical Oncology
ER -